March 14, 2012
FDA Approves Binosto for Osteoporosis
Binosto, a bisphosphonate, is a specific inhibitor of osteoclast-mediated bone resorption. It acts as a chelator of calcium and has a high binding affinity for mineralized bone.
Binosto will be available in packs of 4 and 12 tablets sometime in the third quarter of 2012.
For more information visit www.effrx.com.